Abstract
Overactive bladder syndrome is a chronic condition characterised by urgency, with or without associated urge incontinence. Solifenacin succinate is a once daily, bladder selective antimuscarinic available. The recommended dose is 5 mg once daily and can be increased to 10 mg once daily if 5 mg is well tolerated. We report here a case with dyskinesia emerged following the use of solifenacin, and disappeared in a few days with stopping the agent.
References
- Wagg A, Wyndaele JJ, Sieber P. Efficacy and toler- ability of solifenacin in elderly subjects with overactive bladder syndrome: a pooled analysis. Am J Geriatr Pharmacother 2006;4(1):14-24.
- Chancellor MB, Zinner N, Whitmore K, et al. Efficacy of solifenacin in patients previously treated with tolt- erodine extended release 4 mg: results of a 12-week, multicenter, open-label, flexible-dose study. Clin Ther 2008;30(10):1766-81.
- Basra R, Kelleher C. A review of solifenacin in the treat- ment of urinary incontinence. Ther Clin Risk Manag. 2008;4(1):117-28.
- Cardozo L, Lisec M, Millard R, et al. Randomized, double-blind placebo controlled trial of the once daily antimuscarinic agent solifenacin succinate in patients with overactive bladder. J Urol 2004;172(5):1919-24.
- Suzuki M, Noguchi Y, Okutsu H, Ohtake A, Sasamata M. Effect of antimuscarinic drugs used for overactive bladder on learning in a rat passive avoidance re- sponse test. Eur J Pharmacol 2007;557(2-3):154-8.
- Piecoro LT, Wermeling DP, Schmitt FA, Ashford JW. Seizures in patients receiving concomitant antimus- carinics and acetylcholinesterase inhibitor. Pharma- cotherapy 1998;18(5):1129-32.
Abstract
Aşırı aktif mesane inkontinans olsun ya da olmasın urgency ile ilişkili kronik bir durumdur. Solifenazin günde tek doz kullanılan selektif antimuskarinik bir ajandır. Günde 5 mg olarak başlanır, tolere edilebilirse 10 mg\'a artırılabilir. Biz burada solifenazin kullanımı sonrası ortaya çıkan ve ilacın kesilmesini takiben birkaç gün içinde ortadan kaybolan diskinezili bir olguyu sunduk.
Keywords
References
- Wagg A, Wyndaele JJ, Sieber P. Efficacy and toler- ability of solifenacin in elderly subjects with overactive bladder syndrome: a pooled analysis. Am J Geriatr Pharmacother 2006;4(1):14-24.
- Chancellor MB, Zinner N, Whitmore K, et al. Efficacy of solifenacin in patients previously treated with tolt- erodine extended release 4 mg: results of a 12-week, multicenter, open-label, flexible-dose study. Clin Ther 2008;30(10):1766-81.
- Basra R, Kelleher C. A review of solifenacin in the treat- ment of urinary incontinence. Ther Clin Risk Manag. 2008;4(1):117-28.
- Cardozo L, Lisec M, Millard R, et al. Randomized, double-blind placebo controlled trial of the once daily antimuscarinic agent solifenacin succinate in patients with overactive bladder. J Urol 2004;172(5):1919-24.
- Suzuki M, Noguchi Y, Okutsu H, Ohtake A, Sasamata M. Effect of antimuscarinic drugs used for overactive bladder on learning in a rat passive avoidance re- sponse test. Eur J Pharmacol 2007;557(2-3):154-8.
- Piecoro LT, Wermeling DP, Schmitt FA, Ashford JW. Seizures in patients receiving concomitant antimus- carinics and acetylcholinesterase inhibitor. Pharma- cotherapy 1998;18(5):1129-32.
Details
| Primary Language | Turkish |
|---|---|
| Journal Section | Case Report |
| Authors | |
| Publication Date | December 1, 2012 |
| Published in Issue | Year 2012 Volume: 3 Issue: 4 |